This report presents data on mpox cases reported to the European Surveillance System (EpiPulse Cases). EU/EEA countries report case-based data to ECDC on diagnosed mpox cases. For case numbers by countries, Western Balkans and Türkiye are included.
The epicurve shown includes all mpox cases reported since 2022. The rest of the report includes data on the total number of cases in the past full 12 calendar months (June 2025 to May 2026).
Cases are analysed by date of diagnosis. This report includes cases reported to ECDC as of 16 June 2026.
In May 2026, 94 mpox cases caused by clade I MPXV were reported by 12 countries, with the most cases being reported by Spain (19). In April, 140 cases were reported by 13 countries, and in March, 111 cases were reported by 13 countries.
In May 2026, 22 mpox cases caused by clade II MPXV were reported by six countries, with the most cases being reported by Germany (13). In April, 34 cases were reported by seven countries, and in March, 40 cases were reported by 10 countries.
In the past 12 months, 18 countries reported 608 clade I mpox cases and 19 countries reported 854 clade II mpox cases.
92% of the clade I mpox cases and 92% of the clade II mpox cases with complete information were reported among men who have sex with men.
14% of the clade I mpox cases and 8% of the clade II mpox cases with complete information were hospitalised.
21% of the clade I mpox cases and 17% of the clade II mpox cases with complete information were vaccinated with two doses.
Clade I

Clade II


The distributions by age and gender of clade I and clade II are similar.
The vast majority of mpox cases in both clade I and clade II are among men who have sex with men.
Hospitalisation is higher in clade I mpox cases than in clade II mpox cases.
In the past 12 months there has been one death reported in a person infected with clade II. No deaths reported in people infected with clade I.
Among cases with known vaccination status, the majority of both clade I and clade II mpox cases are not vaccinated.
The proportion of travel-related cases is low and similar between clade I and clade II over the past 12 months.
The number of reported clade I mpox cases in the EU/EEA remains
relatively stable, while clade II mpox cases show a decreasing trend.
Following an increase in late 2025, the number of reported clade
I mpox cases in the EU/EEA continued to rise, with 90 cases reported in
January, 87 in February, 111 in March, and 140 in April. In May, the 94
clade I mpox cases were reported, suggesting a potential slowdown
following the increase observed earlier in 2026.
In contrast,
clade II mpox cases have declined month-to-month.
However,
interpretation of these trends remains limited. Clade information is
missing for approximately 38% of reported cases in the past 12 months,
including 56% of cases reported in May. Cases and epidemiological
information, including clade information, can be updated retrospectively
and may affect the interpretation of short-term trends. Since the last
monthly report, 38 additional clade I mpox cases reported in April have
been added. In addition, one case with co-infection with both clades I
and II was coded as clade II in the dataset.
Clade I mpox case
notifications from EU/EEA suggest ongoing transmission across the
region, primarily among men who have sex with men. In terms of severity,
hospitalisation rates remain low overall but are slightly higher for
clade I than for clade II infections (14% vs 8%). Information from
Member States suggests that clinical presentation is generally mild,
including among hospitalised cases.
Increasing vaccination uptake is the single most important intervention to mitigate the spread of both clades in the spring and summer season. Primary preventive vaccination (PPV) and post-exposure preventive vaccination (PEPV) strategies may be combined to focus on individuals at substantially higher risk of exposure and close contacts of cases, respectively, particularly in the event of limited vaccine supply. PPV strategies should prioritise gay, bisexual, and transgender people, and men who have sex with men, who are at higher risk of exposure, as well as individuals at risk of occupational exposure, based on epidemiological or behavioural criteria. Health promotion interventions and community engagement are also critical to ensure effective outreach and high vaccine acceptance and uptake among those most at risk of exposure.
Further response options for EU/EEA countries include raising awareness among healthcare professionals; supporting sexual health services in case detection, contact tracing, and case management and making testing easily accessible.
The Threat Assessment Brief on the detection of autochthonous transmission of monkeypox virus (MPXV) clade Ib in the EU/EEA’ was published on 24 October, 2025. It summarises the information on the new cases and outlines actions EU/EEA countries can take, as well as the knowledge gaps that remain.
ECDC is continuously monitoring mpox in the EU/EEA and globally through event- and indicator-based surveillance, and remains in contact with partners. ECDC is in contact with affected countries to gather further information and consider response options.
Countries should continue efforts to sequence all positive cases and ensure that sequences are deposited in public repositories (ENA, SRA, and/or GISAID EpiPox) or shared with ECDC through the EpiPulse platform or other means.